Protara Therapeutics (TARA) News Today $4.54 +0.01 (+0.11%) As of 03/27/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Bladder Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and CompaniesMarch 26 at 1:11 AM | theglobeandmail.comCantor Fitzgerald Brokers Lower Earnings Estimates for TARAProtara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Protara Therapeutics in a note issued to investors on Thursday, March 20th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company willMarch 24, 2025 | marketbeat.comAnalyzing Protara Therapeutics (NASDAQ:TARA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI)March 22, 2025 | americanbankingnews.comProtara reveals choline deficiency in parenteral support patientsMarch 21, 2025 | uk.investing.comProtara Therapeutics announces presentation of results from THRIVE-1 studyMarch 21, 2025 | markets.businessinsider.comAnalysts Offer Predictions for TARA FY2025 EarningsMarch 21, 2025 | americanbankingnews.comCantor Fitzgerald Estimates TARA FY2025 EarningsProtara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Protara Therapeutics in a research note issued on Monday, March 17th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will earn ($1.62)March 20, 2025 | marketbeat.comProtara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral SupportMarch 19, 2025 | globenewswire.comProtara Therapeutics, Inc. (NASDAQ:TARA) Short Interest UpdateProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 2,970,000 shares, a drop of 28.4% from the February 13th total of 4,150,000 shares. Based on an average daily volume of 2,310,000 shares, the days-to-cover ratio is presently 1.3 days. Approximately 16.5% of the shares of the company are sold short.March 17, 2025 | marketbeat.comProtara Therapeutics (TARA) Has a New Rating from LifeSci CapitalMarch 15, 2025 | markets.businessinsider.comProtara Therapeutics (NASDAQ:TARA) Coverage Initiated by Analysts at Cantor FitzgeraldCantor Fitzgerald assumed coverage on Protara Therapeutics in a research report on Friday. They set an "overweight" rating on the stock.March 15, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Protara Therapeutics (TARA) with Overweight RecommendationMarch 15, 2025 | msn.comProtara Therapeutics initiated with an Overweight at Cantor FitzgeraldMarch 14, 2025 | markets.businessinsider.comCantor starts Protara with Overweight, sees ‘multi-bagger potential’March 14, 2025 | markets.businessinsider.comAnalysts Issue Forecasts for TARA Q1 EarningsProtara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Analysts at Lifesci Capital issued their Q1 2025 earnings estimates for Protara Therapeutics in a research note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu expects that the company will earn ($0.37) per shareMarch 14, 2025 | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Earns Outperform Rating from Analysts at Lifesci CapitalLifesci Capital started coverage on shares of Protara Therapeutics in a research report on Tuesday. They issued an "outperform" rating and a $22.00 price objective for the company.March 12, 2025 | marketbeat.comLifeSci Capital Initiates Coverage of Protara Therapeutics (TARA) with Outperform RecommendationMarch 11, 2025 | msn.comProtara Therapeutics initiated with an Outperform at LifeSci CapitalMarch 11, 2025 | markets.businessinsider.comHC Wainwright Issues Positive Forecast for TARA EarningsProtara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Stock analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for Protara Therapeutics in a research note issued on Thursday, March 6th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.March 10, 2025 | marketbeat.comFY2029 Earnings Forecast for TARA Issued By HC WainwrightProtara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings estimates for Protara Therapeutics in a report issued on Thursday, March 6th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of ($0.73) per shareMarch 8, 2025 | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research report on Thursday.March 7, 2025 | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth PlansMarch 6, 2025 | finance.yahoo.comTD Cowen Keeps Their Buy Rating on Protara Therapeutics (TARA)March 6, 2025 | markets.businessinsider.comProtara Therapeutics (NASDAQ:TARA) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPSProtara Therapeutics (NASDAQ:TARA - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.09.March 6, 2025 | marketbeat.comProtara Therapeutics Reports Progress and Financial ResultsMarch 5, 2025 | tipranks.comProtara Therapeutics reports Q4 EPS (48c) vs (90c) last yearMarch 5, 2025 | markets.businessinsider.comProtara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateMarch 5, 2025 | globenewswire.comProtara Therapeutics (TARA) Projected to Post Quarterly Earnings on WednesdayProtara Therapeutics (NASDAQ:TARA) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports.March 5, 2025 | marketbeat.comProtara Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | globenewswire.comProtara Therapeutics (NASDAQ:TARA) Stock Price Down 4% - Should You Sell?Protara Therapeutics (NASDAQ:TARA) Trading Down 4% - What's Next?February 25, 2025 | marketbeat.comProtara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | finance.yahoo.comProtara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Decline in Short InterestProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 4,400,000 shares, a drop of 13.7% from the December 31st total of 5,100,000 shares. Based on an average trading volume of 2,270,000 shares, the short-interest ratio is presently 1.9 days.February 1, 2025 | marketbeat.comProtara Therapeutics announces planned 2025 milestonesJanuary 14, 2025 | markets.businessinsider.comProtara Therapeutics: Protara Highlights Recent Updates and Anticipated 2025 MilestonesJanuary 13, 2025 | finanznachrichten.deProtara Highlights Recent Updates and Anticipated 2025 MilestonesJanuary 13, 2025 | globenewswire.comProtara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | finance.yahoo.comProtara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 79.1% in DecemberProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 5,410,000 shares, an increase of 79.1% from the November 30th total of 3,020,000 shares. Based on an average daily trading volume, of 2,200,000 shares, the short-interest ratio is currently 2.5 days.December 27, 2024 | marketbeat.comProtara Therapeutics: Rising From The AshesDecember 14, 2024 | seekingalpha.comProtara Therapeutics Raises $100M in Stock OfferingDecember 11, 2024 | markets.businessinsider.comProtara Announces Closing of $100 Million Public OfferingDecember 11, 2024 | globenewswire.comProtara Therapeutics announces common stock offering, no amount givenDecember 11, 2024 | markets.businessinsider.comProtara Therapeutics 13.69M share Spot Secondary priced at $6.25December 10, 2024 | markets.businessinsider.comProtara Therapeutics: Carving New Roads In Bladder CancerDecember 10, 2024 | seekingalpha.comProtara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 CatalystDecember 10, 2024 | seekingalpha.comProtara Prices Public Offering Of 13.69 Mln Shares At $6.25/Shr, To Raise $100 MlnDecember 10, 2024 | markets.businessinsider.comProtara Announces Pricing of $100 Million Public OfferingDecember 9, 2024 | globenewswire.comProtara Announces Proposed Public OfferingDecember 9, 2024 | globenewswire.comInstitutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the mostDecember 7, 2024 | finance.yahoo.comProtara Therapeutics (NASDAQ:TARA) Given "Buy" Rating at GuggenheimGuggenheim restated a "buy" rating and set a $20.00 price target on shares of Protara Therapeutics in a report on Friday.December 6, 2024 | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $23.00 target price on shares of Protara Therapeutics in a report on Friday.December 6, 2024 | marketbeat.com Remove Ads Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address TARA Media Mentions By Week TARA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARA News Sentiment▼0.150.78▲Average Medical News Sentiment TARA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARA Articles This Week▼92▲TARA Articles Average Week Remove Ads Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AVBP News ORGO News CVAC News GHRS News NUVB News CRMD News IMNM News ABUS News BCYC News DNTH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
